Subject
Neurology (clinical),Neurology,General Medicine
Reference45 articles.
1. Alemtuzumab (Lemtrada®). Summary of product characteristics. September 2018. Available on https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_en.pdf last accessed 31 January 2023.
2. Management of multiple sclerosis in the breastfeeding mother;Almas;Mult. Scler. Int.,2016
3. Pharmacotherapeutic considerations in women with multiple sclerosis;Andersen;Expert Opin. Pharmacother.,2020
4. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study;Ciplea;Mult. Scler.,2022
5. Safety of potential breastmilk exposure to IFN-β or glatiramer acetate: one-year infant outcomes;Ciplea;Neurol. Neuroimmunol. Neuroinflamm.,2020